Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Guardant Health, Inc. is a precision oncology company that develops and commercializes blood-based and tissue-based molecular diagnostic tests, commonly referred to as liquid biopsies. The company operates within the biotechnology and clinical diagnostics industries, with a primary focus on oncology. Its technologies are designed to detect genomic alterations in cancer, enabling treatment selection, therapy monitoring, and disease recurrence detection using minimally invasive methods.
The company’s core revenue is generated from clinical diagnostic testing and biopharmaceutical services, primarily through its proprietary liquid biopsy platforms. Guardant Health serves oncologists, hospitals, biopharmaceutical companies, and research institutions, with a strategic emphasis on advanced cancer diagnostics and early cancer detection. Founded in 2012, the company has evolved from a single-product diagnostics firm into a multi-platform oncology diagnostics provider, achieving multiple regulatory approvals and expanding into population-scale cancer screening research.
Business Operations
Guardant Health operates primarily through two reportable business segments: GuardantINFORM and LUNAR. The GuardantINFORM segment encompasses the company’s oncology testing and biopharmaceutical services, including commercially available tests such as Guardant360 CDx, GuardantOMNI, and INFORM data solutions, which generate revenue through clinical testing and partnerships with drug developers. This segment represents the majority of current commercial revenue.
The LUNAR segment is focused on early cancer detection and minimal residual disease testing, including LUNAR-1 and LUNAR-2, which are in various stages of development and clinical validation. Guardant Health conducts operations primarily in the United States, with international testing and commercial activities supported through subsidiaries and distributors. The company controls proprietary next-generation sequencing technology, large-scale clinical-genomic databases, and regulated laboratory infrastructure.
Strategic Position & Investments
Guardant Health’s strategy centers on expanding its leadership in liquid biopsy diagnostics while advancing into large-scale cancer screening and longitudinal disease monitoring. Growth initiatives include broadening FDA-approved companion diagnostics, deepening biopharmaceutical partnerships, and scaling data-driven oncology insights through its testing platforms. The company has made significant long-term investments in early cancer detection, which management has identified as a transformational opportunity despite near-term operating losses.
Strategically, Guardant Health has pursued selective acquisitions and internal development rather than large-scale consolidation. Notable investments include the acquisition of Bellwether Bio, which strengthened its minimal residual disease capabilities. The company remains actively involved in emerging applications of genomics, real-world evidence generation, and decentralized clinical trials through its diagnostic and data platforms.
Geographic Footprint
Guardant Health is headquartered in Redwood City, California, and operates primarily across North America, which accounts for the majority of its revenue and clinical testing volume. The company maintains a growing presence in Europe and Asia-Pacific, supported by international laboratories, partnerships, and distributor agreements.
Its tests are used by healthcare providers and pharmaceutical companies in multiple countries, and the company continues to pursue regulatory approvals and market entry in additional regions. While international operations currently represent a smaller share of revenue, they are considered strategically important for long-term growth and global clinical trial support.
Leadership & Governance
Guardant Health was co-founded by Helmy Eltoukhy and AmirAli Talasaz, who established the company with a focus on applying advanced genomics to improve cancer care. The leadership team emphasizes scientific rigor, regulatory credibility, and long-term investment in innovation, particularly in early cancer detection.
Key executives include:
- Helmy Eltoukhy – Co-Founder, Chairman, and Chief Executive Officer
- AmirAli Talasaz – Co-Founder and Chief Technology Officer
- Michael Bell – Chief Financial Officer
- Ian Clark – President
- Leah S. Granados – Chief Commercial Officer
The board and executive team collectively guide strategy with a stated vision of transforming cancer detection and treatment through accessible, accurate, and data-driven diagnostics.